Company: Deciphera Pharmaceuticals
Symbol: DCPH
Description: They are a clinical-stage biopharmaceutical company developing new drugs to improve the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of many cancer therapies.
Shares: 6.25 million
Price Range: $15.00-$17.00
Trade Date: 9/28
Underwriter(s): J.P. Morgan, Piper Jaffray
Co-Manager(s): JMP Securities, Nomura
Business: Their targeted, small molecule drug candidates, designed using their proprietary kinase switch control inhibitor platform, inhibit the activation of kinases, an important family of enzymes, that, when mutated or over expressed, are known to be directly involved in the growth and spread of many cancers. They have built a diverse pipeline of wholly owned, orally administered drug candidates that include three clinical-stage and two research-stage programs. They have designed our lead drug candidate DCC-2618 to inhibit the full spectrum of mutant or amplified KIT and PDGFRα kinases that drive cancers such as gastrointestinal stromal tumors, or GIST.
Competition and Sector Performance: Healthcare Related IPOs as of 9.21.17pm
Insider Buying: Certain of their existing stockholders have indicated an interest in purchasing up to an aggregate of approximately $30 million of shares of their common stock.
Book-Building Status: The way the book comes together during the week of the roadshow is the most critical indicator to first-day and first-week performance. IPO Boutique uses its 45 years of experience and sources all over the street to gather daily subscription levels, specific price guidance and what type of investors are currently in the book or are anchoring orders in the book. In addition, recent underwriter performance on sector specific deals is a strong factor that IPO Boutique takes into account when determining if our clients should indicate for any offering.
IPO Boutique subscription clients receive daily updates on this critical information.
Conclusion: IPO Boutique provides ratings, daily commentary and a forecast for how this IPO will open vs. its offering price. We have kept a track record with our performance for last 12 years at our website.
Indicate with confidence, SUBSCRIBE today.
English
Arabic
Chinese (Simplified)
Dutch
French
German
Italian
Portuguese
Russian
Spanish